BioCryst Pharmaceuticals, Inc. (BCRX)
Nasdaq · Healthcare · Drug Manufacturers - Specialty & Generic
$8.10−0.86%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $2.1B
- Forward P/E
- 8.6
- 52-week range
- $6.00 – $11.22
- 52-week change
- +17.55%
- EPS (trailing)
- −$1.40
- Analyst rating
- 1.5 Strong buy
- Next earnings
- Nov 2, 2026
Fiscal year to Dec 2025
- Revenue
- $875M (+94.10%)
- Net income
- $264M
- Operating margin
- 39.0%
- Diluted EPS
- $1.21
- Free cash flow
- $345M
From the company’s annual report on SEC EDGAR.
About BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial.
Headquarters: Durham, United States · 435 employees · biocryst.com